Abstract
During the course of the 2015-2017 outbreak of Zika virus (ZIKV) infection in the Americas, the emerging virus was recognized as a congenital infection that could damage the developing brain. As the Latin American ZIKV outbreak advanced, the scientific and public health community questioned if this newly recognized neurotropic flavivirus could affect the developing brain of infants and young children infected after birth. We report here the design, methods and rapid operationalization of a prospective natural history cohort study aimed at evaluating the potential neurological and neurodevelopmental effects of postnatal Zika virus infection in infants and young children, which had become epidemic in Central America. This study enrolled a cohort of 500 mothers and their infants, along with nearly 400 children 1.5-3.5 years of age who were born during the initial phase of the ZIKV epidemic in a rural area of Guatemala. Our solutions and lessons learned while tackling real-life challenges may serve as a guide to other researchers carrying out studies of emerging infectious diseases of public health priority in resource-constrained settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a National Institutes of Allergy and Infectious Diseases at the National Institutes of Health contract funding to the Vaccine and Treatment Evaluation Units (VTEUs) at Baylor College of Medicine HHSN272201300015I. Task Order No. HHSN27200013-16-0057.C1D1.0058. Agro-America and the Center for Global Health at the University of Colorado provided ongoing funding for the Center for Human Development and the Creciendos Sanos Program at FUNSALUD from where the study was implemented and operationalized. REDCap utilization was supported by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Boards of BCM, CU (COMIRB), and the Ministry of Public Health and Social Welfare (MSPAS) of Guatemala in May of 2017.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
↵¶ Co-Senior authors
Data Availability
All relevant data are within the manuscript and its Supporting Information files.